The size of the Melanoma Therapeutics Market in the Asia Pacific was worth USD 0.78 billion in 2020 and estimated to be growing at a CAGR of 16.40%, to reach USD 1.66 billion by 2025.
The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.
The elevated demand for innovative early-stage and advanced melanoma treatments along with a thriving patient base has generated an imminent need for improved therapies in the melanoma market. Even though a plethora of treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive in the market. Large acceptance of these new treatments is projected due to their enhanced survival benefits and negligible side effects.
The growth of the Asia-Pacific Melanoma Therapeutics market is mainly due to factors such as the rise in the number of melanoma cases, and growing awareness towards it.
However, volatile economies and poor accessibility of proper cancer care in this part of the world are the key factors hindering the growth of the market in this region.
This research report on the APAC Melanoma Therapeutics Market is segmented and sub-segmented into the following categories:
By Cancer Stage:
By Cancer Type:
By Diagnosis:
By Treatment:
By Country:
The Asia-Pacific Melanoma Therapeutics market is projected to grow at the highest CAGR during the forecast period due to reasons such as a large population base and rising prevalence of melanoma. China is the largest market for Melanoma Therapeutics in this region followed by India.
The Top companies leading in the APAC Melanoma Therapeutics Market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By cancer stage
5.1.1 Stage 0
5.1.2 Stage I
5.1.3 Stage II
5.1.4 Stage III
5.1.5 Stage IV
5.2 By cancer type
5.2.1 Nodular melanoma
5.2.2 Acral lentiginous melanoma
5.2.3 Superficial spreading melanoma
5.2.4 Lentigno maligna melanoma
5.2.5 Amelanotic melanoma
5.2.6 Others
5.3 By Diagnosis
5.3.1 Ultrasound
5.3.2 Blood Tests
5.3.3 Dermatoscopy
5.3.4 Sentinel lymph node biopsy
5.3.5 X-rays
5.3.6 CT Scan
5.4 By Treatment
5.4.1 Early melanoma
5.4.2 Advanced melanoma
5.4.2.1 Biological therapy
5.4.2.2 Targeted therapy
5.4.2.3 Surgery
5.4.2.4 Chemotherapy
5.4.2.5 Radiotherapy
5.4.2.6 Immune therapy
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Bristol-Myers Squibb Co
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Merck and Co
9.3 F. Hoffmann-La Roche
9.4 Amgen Inc
9.5 Celgene Corp
9.6 Daiichi Sankyo
9.7 Pfizer Inc
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
